(Q44748178)

English

Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study

scientific article published in January 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 December 2017

Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study (English)

1 reference

Europe PubMed Central

5 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Athanasios Dimopoulos

1

1 reference

Europe PubMed Central

5 December 2017

author name string

Christos Kiamouris

2

1 reference

Europe PubMed Central

5 December 2017

Dimitra Gika

3

1 reference

Europe PubMed Central

5 December 2017

Charalambos Deliveliotis

4

1 reference

Europe PubMed Central

5 December 2017

Aris Giannopoulos

5

1 reference

Europe PubMed Central

5 December 2017

Anastasios Zervas

6

1 reference

Europe PubMed Central

5 December 2017

Christos Alamanis

7

1 reference

Europe PubMed Central

5 December 2017

Constantinos Constantinidis

8

1 reference

Europe PubMed Central

5 December 2017

Michael Koutsilieris

9

1 reference

Europe PubMed Central

5 December 2017

language of work or name

0 references

publication date

1 January 2004

1 reference

Europe PubMed Central

5 December 2017

1 reference

Europe PubMed Central

5 December 2017

63

1 reference

Europe PubMed Central

5 December 2017

120-125

1 reference

Europe PubMed Central

5 December 2017

1

1 reference

Europe PubMed Central

5 December 2017

Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Oral estramustine and oral etoposide for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

The chemotherapy of urologic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Weekly doxorubicin in endocrine-refractory carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Nuclear protein matrix as a target for estramustine-induced cell death

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.041

7 January 2021

Identifiers

10.1016/J.UROLOGY.2003.08.041

1 reference

Europe PubMed Central

5 December 2017

1 reference

Europe PubMed Central

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44748178&oldid=2135556581"